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ABSTRACT
Folding of the LTR promoter into dynamic G-
quadruplex conformations has been shown to sup-
press its transcriptional activity in HIV-1. Here
we sought to identify the proteins that control
the folding of this region of proviral genome by
inducing/stabilizing G-quadruplex structures. The
implementation of electrophorethic mobility shift as-
say and pull-down experiments coupled with mass
spectrometric analysis revealed that the cellular
protein nucleolin is able to specifically recognize
G-quadruplex structures present in the LTR pro-
moter. Nucleolin recognized with high affinity and
specificity the majority, but not all the possible G-
quadruplexes folded by this sequence. In addition,
it displayed greater binding preference towards DNA
than RNA G-quadruplexes, thus indicating two levels
of selectivity based on the sequence and nature of
the target. The interaction translated into stabiliza-
tion of the LTR G-quadruplexes and increased pro-
moter silencing activity; in contrast, disruption of nu-
cleolin binding in cells by both siRNAs and a nucle-
olin binding aptamer greatly increased LTR promoter
activity. These data indicate that nucleolin possesses
a specific and regulated activity toward the HIV-1
LTR promoter, which is mediated by G-quadruplexes.
These observations provide new essential insights
into viral transcription and a possible low mutagenic
target for antiretroviral therapy.
INTRODUCTION
G-quadruplexes (G4s) are nucleic acids secondary struc-
tures that may form in single-stranded G-rich DNAs and
RNAs under physiological conditions (1–3). Four Gs bind
via Hoogsteen-type hydrogen bonds to yield G-quartets
that in turn stack on top of each other to form the G4.
G4s are highly polymorphic, both in terms of strand sto-
ichiometry (forming both inter- and intramolecular struc-
tures) and strand orientation/topology. The presence of K+
cations specifically supports G4 formation and stability (4–
6). In eukaryotes and prokaryotes, G4 DNA motifs have
been found in telomeres, G-rich micro- and mini-satellites,
near promoters, and within the ribosomal DNA (rDNA)
(7–9). In the human genome, genes that are near G4 DNA
motifs fall into specific functional classes; for example, pro-
moters of oncogenes and tumor suppressor genes have par-
ticularly high and low G4-forming potential, respectively
(10–12). Human G4 DNA motifs have been reported to
be associated with recombination prone regions (13) and
to show mutational patterns that preserved the potential to
formG4 DNA structures (9). RNAG4s have been detected
in the 5′ and 3′-UTR and coding regions, in which they act
as important regulators of pre-mRNA processing (splicing
and polyadenylation), RNA turnover, mRNA targeting and
translation (14,15). Regulatory mechanisms controlled by
G4s involve the binding of protein factors that modulate
G4 conformation and/or serve as a bridge to recruit addi-
tional protein regulators. Indeed, G4 binding proteins can
be classified into three functional groups: telomere-related
proteins, such as the shelterin complex; proteins that unfold
theG4 structure, such as the helicase and heterogeneous nu-
clear ribonucleoprotein families; proteins that stabilize G4s,
a large group which includes nucleolin, MAZ and nucle-
ophosmin (3,16–18).
G4 structures and their cognate proteins are key players
in numerous essential processes in eukaryotic cells. Their
misregulation has been associated with a number of rele-
vant human diseases, such as the amyotrophic lateral sclero-
sis (19–21), Alzheimer (22) and fragile X syndrome (23), in
which expansion of G4-forming regions has been reported.
Moreover, mutations in G4-interacting proteins have been
linked to genetic diseases, such as theWerner syndrome and
Fanconi anemia (24,25). In recent years, new studies have
*To whom correspondence should be addressed. Tel: +39 498272346; Fax: +39 498272355; Email: sara.richter@unipd.it
C© The Author(s) 2015. Published by Oxford University Press on behalf of Nucleic Acids Research.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which
permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
 at U
niversita D
egli Studi D
i Padova on O
ctober 15, 2015
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
Nucleic Acids Research, 2015, Vol. 43, No. 18 8885
contributed to increase our knowledge of the biological sig-
nificance of G4s in prokaryotes (26,27) and viruses (28).
We and other groups have identified functionally significant
G4s in the Nef coding region (29) and the unique LTR pro-
moter (30–32) of the human immunodeficiency virus (HIV),
the etiologic agent of the acquired immune deficiency syn-
drome (AIDS). These studies have shown that G4 folding
at the LTR promoter decreased viral transcription with an
effect that was augmented by G4 ligands (30,33). In this di-
rection, the significance of these structures as focal points
of interactions with host and viral factors is supported also
by the observation that G4-folded sequences are specifically
recognized by various viral proteins, such as the Epstein
Barr Virus Nuclear Antigen 1 (34,35) and the SARS coro-
navirus unique domain (SUD), which occurs exclusively
in highly pathogenic strains (36). For this reason, we de-
cided to pursue the investigation of putative cellular/viral
proteins that may be involved in the regulation of the G4
LTR promoter activity in HIV. We employed a concerted
approach combining electrophorethic mobility shift assay
(EMSA) and analysis by electrospray ionization mass spec-
trometric (ESI-MS) to identify possible factors capable of
binding the LTRG4 structure. In order to validate the find-
ings, we then tested their stabilizing activity on the G4 fold
and evaluated their ability to inhibit LTR-driven transcrip-
tion in cells. The results provided new insights into the role
of the LTR G4 in the viral life cycle, which could pave
the way for the possible development of novel therapeutic
strategies.
MATERIALS AND METHODS
Oligonucleotides, plasmids and aptamers
All desalted oligonucleotides and aptamers were purchased
from Sigma-Aldrich, Milan, Italy (Supplementary Table
S1). The HIV-1 LTR region was inserted into the promoter-
less luciferase reporter vector pGL4.10-Luc2 (Promega
Italia, Milan, Italy) to form the pGL4.10-LTR-Luc2 vec-
tor, as previously reported (30). The Renilla plasmid (p4.74,
Promega Italia, Milan, Italy) was used as an internal
control. The human enhanced green fluorescent protein-
nucleolin plasmid (GFP-Nucleolin) was purchased from
Addgene (Addgene, Cambridge, MA, USA). The pEGFP
empty vector was used as control (Clontech, Takara Bio,
Otsu, Japan).
Cell culturing
Human embryonic kidney (HEK) 293T cells (ATCC
# CRL-3216) were grown in DMEM (Gibco, Thermo
Fisher Scientific, Waltham, MA, USA) supplemented with
10% heat-inactivated fetal bovine serum (FBS, Gibco,
Thermo Fisher Scientific, Waltham, MA, USA). Jurkat T-
lymphocytes cells (ATCC # TIB-152) were grown in RPMI
1640 (Gibco, Thermo Fisher Scientific, Waltham, MA,
USA) supplemented with 10% heat-inactivated FBS.MCF-
7 human breast cancer cells (ATCC #HTB-22) were grown
in RPMI 1640 supplemented with 10% heat-inactivated
FBS. MCF10A normal human mammary epithelial cells
(ATCC #CRL-10317) were grown in DMEM/F12 (Gibco,
Thermo Fisher Scientific, Waltham, MA, USA) supple-
mented with 10% heat-inactivated FBS and EGF (0.02
g/ml), hydrocortisone (0.5 g/ml), cholera toxin (0.1
g/ml), insulin (10 g/ml) (purchased all from Sigma-
Aldrich, Milan, Italy). All cultures were grown in a humid-
ified incubator maintained at 37◦C with 5% CO2.
Protein nuclear extraction and electrophoretic mobility shift
assay (EMSA)
Oligonucleotides were 5′-end labeled with [ -32P]ATP using
T4 polynucleotide kinase at 37◦C for 30 min. After DNA
precipitation, labeled species were resuspended in lithium
cacodylate buffer (10 mM, pH 7.4) and KCl 100 mM. The
oligonucleotides were denatured for 5min at 95◦Cand grad-
ually cooled to room temperature to achieve proper fold-
ing of G-quadruplex structures. Protein nuclear extracts of
HEK 293T and Jurkat cells were obtained by using NX-
TRACT kit (Sigma-Aldrich, Milan, Italy). Recombinant
full-length human nucleolin was expressed in HEK293 cells
and purified as described by the manufacturer (Origene
Technologies, Rockville, USA). Labeled oligonucleotides
(40 nM) were incubated in 20 l of reaction in EMSA bind-
ing buffer and nuclear extract (0.5 g/l) or purified nucle-
olin (300 ng) for 2 h at 37◦C. EMSA binding buffer compo-
sition was: Tris–HCl 20 mM, pH 8, KCl 30 mM,MgCl2 1.5
nM, DTT 1 mM, glycerol 8%, protease inhibitor cocktail
(Sigma-Aldrich, Milan, Italy) 1%, NaF 5 mM, Na3VO4 1
mM, poly [dI-dC] (Sigma-Aldrich,Milan, Italy) 1.25 ng/l.
In competition experiments, an excess of cold oligonu-
cleotides was added to the samples and their ability to dis-
rupt the G4 structures was monitored to evaluate binding
specificity. After incubation, reaction solutions were loaded
onto 5% native polyacrylamide gel in 1× TBE buffer and
KCl 100 mM. DNA–protein complexes were resolved by
running the gel overnight at 27 V at 4◦C. EMSA gels were
dried using a gel dryer (Bio-RadLaboratories,Milan, Italy),
free and bound DNA molecules were visualized by phos-
phorimaging (Typhoon FLA9000, GE Healthcare Europe,
Milan, Italy) and quantified by ImageQuant TL Software
(GE Healthcare Europe, Milan, Italy). After the desired
complexwas located on the gel, the corresponding bandwas
cut and either directly in-gel digested for mass spectromet-
ric (MS) analysis, or further purified by SDS-PAGE. Ex-
traction was performed in SDS-PAGE sample buffer. After
5 min in boiling water, samples were incubated overnight at
37◦C. Finally, supernatant was loaded on 12% SDS-PAGE.
The band of interest was excised after coomassie staining.
Protein extraction from HIV-1 infected cells
HEK 293T cells were seeded in a 10-cm dish in DMEM
supplemented with 10% heat-inactivated FBS and incu-
bated overnight. Cells were next either mock-transfected
or transfected with of pNL4-3 (the reagent was obtained
throughout the NIH AIDS Reagent Program, Division of
AIDS, NIAID, NIH) (37) using CalPhosTM Mammalian
Transfection Kit (Clontech, Otsu, Japan) according to the
manufacturer’s protocol. After 8 h, cells were washed with
PBS 1× and fresh growth medium was added. Forty eight
hours post-transfection, cells were washed twice with cold
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PBS and scraped off. After a short centrifugation, pellet
was resuspended in total protein extraction buffer (KCl
600 mM, Tris–HCl 20 mM, pH 7.8, glycerol 20%, DTT 2
mM, protease inhibitor cocktail). Cells were then lysed with
three repeated freeze/thaw cycles and supernatant cleared
by centrifugation, stored at −80◦C, and subsequently used
in EMSA assays.
Mass spectrometric (MS) protein identification
Bands were treated according to established in-gel diges-
tion protocols. Briefly, they were first washed with 50%
CH3OH and 2.5% acetic acid, dehydrated with CH3CN,
and then reduced with 30 l of DTT (10 mM in 100 mM
NH4HCO3) for 30 min at room temperature. The excess of
DTT was eliminated before treating the bands with 30 l of
iodoacetamide (50 mM in 100 mM NH4HCO3) for 30 min
at room temperature in order to alkylate cysteine residues.
Bands were washed with 100 mM NH4HCO3, dehydrated
with CH3CN twice, and then digested. A 1 g aliquot
of MS-grade trypsin (ThermoFisher Scientific, Waltham,
MA, USA) in 50 l of 50 mM NH4HCO3 was added to
the dehydrated bands, followed by incubation on ice for 30
min. The excess of trypsin was eliminated and substituted
with 20 l of 50 mM NH4HCO3 and the sample was in-
cubated overnight at 37◦C. Peptides were extracted twice
with 5% formic acid and twomore times with 50%CH3CN,
5% formic acid. The peptide mixture was further desalted
in a silica nanocolumn (Polymicro Technologies, Phoenix,
AZ, USA) packed in house with pinnacle C18 pack mate-
rial (Thermo Fisher Scientific, Waltham, MA, USA). All
materials were MS grade purchased from Sigma Aldrich,
St. Louis, MO, US except where otherwise indicated.
The desalted mixture was finally analyzed by direct in-
fusion electrospray ionization (ESI) on a Thermo Fisher
Scientific (Waltham, MA, USA) LTQ-Orbitrap Velos mass
spectrometer. The instrument was calibrated by using a 0.5
mg/ml solution of CsI in 50% CH3OH, which provided a
typical<2 ppmmass accuracy. All analyses were performed
in nanoflow mode by utilizing quartz emitters produced in
house by using a P2000 laser pipette puller (Sutter Instru-
ments Co., Novato, CA, USA). Up to 5 l samples were
typically loaded onto each emitter by using a gel-loader
pipette tip. A stainless steel wire was inserted through the
back-end of the emitter to supply an ionizing voltage that
ranged between 0.8 and 1.2 kV. Bands containing bovine
serum albumin (BSA) and empty gel bands were used as
positive and negative control, respectively. Putative peptides
that were not present in blank samples were submitted to
tandem mass spectrometric (MS/MS) analysis. These de-
terminations involved isolating the precursor ion of inter-
est in the LTQ element of the instrument, activating frag-
mentation in either the LTQ or the C-trap, and performing
fragment detection in the Orbitrap. The masses of the 50
more intense fragments were employed to perform a Mas-
cot Database Search (38) to identify their parent protein.
The matched protein was deemed as being positively iden-
tified when two or more peptides provided a mascot score
greater than 22.
Pull-down assay
HEK 293T protein nuclear extract (0.6 g/l) was incu-
bated with biotinylated LTR oligo G4 folded (600 nM) in
250 l of reaction containing Tris–HCl 20 mM, pH 8, KCl
30 mM, MgCl2 1.5 nM, protease inhibitor cocktail 1%,
NaF 5 mM, Na3VO4 1 mM, poly [dI-dC] 1.25 ng/l for
2 h at 37◦C. The binding reaction was followed by incuba-
tion (2 h at 37◦C) with 30 l of streptavidin-agarose beads
(Sigma-Aldrich, Milan, Italy). After PBS washes, proteins
were eluted with increasing amount of NaCl (0.2 and 1M),
and concentrated with Amicon Ultra 0.5 (MerckMillipore,
Germany). Beads were collected by brief centrifugation, re-
suspended in 50 l of Laemmli buffer, and finally incubated
at 95◦C for 5 min. Supernatants were separated on SDS-
PAGE and analyzed by western blot.
FRET-melting assay
Oligonucleotides were diluted to 0.1 M in lithium cacody-
late buffer (10 mM, pH 7.4) and KCl 100 mM heat dena-
tured for 5 min at 95◦C, and folded in G4 structure at room
temperature for 16 h. Samples were incubated alone, with
purified human nucleolin (530 ng) or bovine serum albu-
min (BSA, negative control) for 1h at 37◦C. Fluorescence
melting curves were determined by using a LightCycler II
(Roche,Milan, Italy). After a first equilibration step at 30◦C
for 2 min, a stepwise increase of 1◦C every minute for 65 cy-
cles was performed to reach 95◦C.Ameasurementwas com-
pleted after each cycle by using 470 nm excitation and 530
nm detection. Oligonucleotide melting was monitored by
observing 6-carboxyfluorescein (6-FAM) emission, which
was normalized between 0 and 1.Tm was defined as the tem-
perature for which the normalized emission was 0.5.
siRNA and luciferase reporter assay
Gene-specific pooled siRNA trilencer targeting human
NCL and a scrambled negative control duplex were pur-
chased from Origene (NCL Trilencer-27 Human siRNA,
OriGene Technologies, Rockville, MD, USA). MCF7 cells
were transfected with 1, 2 and 4 nM aliquots of hu-
man NCL siRNA and control siRNA by using Lipo-
fectamine RNAiMAX (Invitrogen, Thermo Fisher Scien-
tific, Waltham,MA, USA) following the manufacturer’s in-
structions. pLTR luciferase plasmid and Renilla construct
were transfected into the same cells 24 h later by using
Lipofectamine 3000 (Invitrogen, Thermo Fisher Scientific,
Waltham, MA, USA). In the double transfected cells, LTR
promoter activity was assessed as firefly luciferase signal,
normalized to Renilla luciferase activity, by using Dual-
Glo R© Luciferase Assay System (Promega Italia, Milan,
Italy), according to the manufacturer’s directions (30). De-
pending on the transfected cell line (i.e. either MCF7 or
MCF10A), the pGL4.10-LTR-Luc2 vector provided signals
ranging form 103 to 2 × 106 luciferase units, as measured
by a Victor X2 multilabel plate reader (Perkin Elmer Italia,
Milan, Italy). In contrast, the promoterless pGL4.10-Luc2
and untransfected cells displayed a background signal lower
than 10 luciferase units. All data were acquired in medium-
free PBS. DNA aptamers AS1411 and the control CRO26
were added to cell medium at the time of transfection of
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pGL4.10-LTR-Luc2 and p4.74-Renilla plasmids and the lu-
ciferase signal read 24 h after transfection. Each assay was
performed in duplicate and each set of experiments was re-
peated at least three times.
Immunoblot analysis
Immunoblot analysis was performed on cell protein ex-
tracts obtained as previously described (39). Protein con-
centrations were quantified by using the Pierce R© BCA Pro-
tein Assay Kit (Thermo Scientific, Rockford, IL, USA)
and the samples stored at −80◦C. Each sample was elec-
trophoresed on 12% SDS-PAGE and transferred to a nitro-
cellulose blotting membrane (Amersham TM Protan TM,
GE Healtcare Life science, Milan, Italy) by using trans-
blot SD semi-dry transfer cell (Bio-Rad Laboratories, Mi-
lan, Italy). Themembranes were blocked with 5% skimmilk
in PBST (0.05% Tween 20 in PBS). Membranes were incu-
bated with the respective primary antibody directed against
NCL (rabbit polyclonal C23 (H-250); Santa Cruz Biotech-
nology, Dallas, TX, USA), p24 (rabbit polyclonal; Abcam,
Cambridge, UK), and -actin (mouse monoclonal; Sigma-
Aldrich, Milan, Italy). After three washes in PBST, mem-
branes were incubated with ECL Plex Goat--Rabbit IgG-
Cy5 or ECL Plex Goat--Mouse IgG-Cy5 (GE Healthcare
Life sciences,Milan, Italy). Images were captured on the Ty-
phoon FLA 9000, and quantified by ImageQuant TL soft-
ware.
Taq polymerase stop assay
Taq polymerase stop assay was carried out as previ-
ously described (30). Briefly, the 5′-end labeled primer (5′-
GGCAAAAAGCAGCTGCTTATATGCAG-3′) was an-
nealed to the template (Supplementary Table S1) in lithium
cacodylate buffer in the presence or absence of KCl 100mM
by heating at 95◦C for 5 min and gradually cooling to room
temperature. Where specified, samples were incubated with
purified human nucleolin (61 ng) at 37◦C for 2 h. Primer ex-
tension was then conducted by using 2U of AmpliTaqGold
DNApolymerase (Life Technologies, ThermoFisher Scien-
tific) for 30 min at 37◦C or 47◦C. Reactions were stopped by
ethanol precipitation. Primer extension products were sep-
arated on a 15% denaturing gel, and finally visualized by
phosphorimaging (Typhoon FLA 9000).
Dimethylsulfate footprinting
The DNA substrate of interest was gel-purified before use
and prepared in desalted/lyophilised form. The oligonu-
cleotide was 5′-end-labeled with [ -32P]ATP by T4 polynu-
cleotide kinase, purified by using MicroSpin G-25 columns
(Amersham Biosciences, Europe), resuspended in lithium
cacodylate buffer 10 mM, pH 7.4, KCl 100 mM, heat-
denatured and folded. The oligonucleotide (1.23 M) was
incubated either alone or with purified human nucleolin
(300 ng) in EMSAbinding buffer for 2 h at 37◦C. Sample so-
lutions were then treated with dimethylsulfate (DMS, 0.5%
in ethanol) for 5 min and stopped by addition of gel load-
ing buffer containing 10% glycerol and -mercaptoethanol.
Samples were loaded onto 16% native polyacrylamide gels
and run until the desired resolution was obtained. DNA
bands were localized via autoradiography, excised and
eluted overnight. The supernatantswere recovered, ethanol-
precipitated and treated with piperidine 1M for 30 min at
90◦C. Samples were dried in a speed-vac, washed with wa-
ter, dried again and resuspended in formamide gel loading
buffer. Reaction products were analyzed on 20% denaturing
polyacrylamide gels, visualized by phosphorimaging analy-
sis, and quantified by ImageQuant TL software.
Surface plasmon resonance (SPR) analysis
SPR was performed on the Biacore T100 platform (GE
Healthcare, Life Science, Milan, Italy). Purified human
NCL was immobilized on Serie S sensor chip CM5 by
amine coupling. Immobilizationwas performed inHEPES–
NaCl running buffer (HEPES pH 7.4 0.01 M, NaCl 0.15
M, EDTA 3 mM). The protein diluted in sodium acetate
buffer pH 4.0 at the concentration of 15 ng/l was injected
to reach the response of around 1000 RU. Blank immobi-
lization was performed in the flow cell 1 to permit reference
subtraction. LTR-II+III+IV wt and scrambled sequences
binding analysis was performed at a flow rate of 25 l/min,
with contact time of 180 s and dissociation time of 240 s in
HEPES-KCl buffer (HEPES pH 7.4 15 mM, KCl 0.25 M,
EDTA 3 mM). Oligonucleotides were diluted from stock to
the concentration of 2 M in HEPES-KCl buffer, denatu-
rated at 95◦C for 5 min and allowed to cool at room temper-
ature to permit G4 formation. Sensograms were obtained
in the concentration range of 31.25 nM–2 M. After each
oligonucleotide injection the chip surface was regenerated
with KCl 1M solution. All sensograms were corrected by
reference subtraction of blank flow cell response and buffer
injection response. Data were fitted to a 1:1 binding model
with Rmax initial parameter set to theoretical calculated
Rmax of 157 using BIAevaluation software (GE Health-
care).
RESULTS
A cellular protein binds specific G-quadruplexes of the HIV-1
LTR promoter
In previous work, we demonstrated that the HIV-1 LTR
region can fold at least three different G-quadruplex (G4)
structures at positions −92/−48 with respect to the tran-
scription initiation site of the representative HXB2 LAI
(NC 001802) strain (30). Disruption of G4 by point mu-
tations increased the transcript levels, thus indicating that
G4 formation may contribute to the modulation of viral
transcription. We reasoned that stabilization and unfolding
of G4 at the LTR level are likely regulated by interactions
with viral/cellular proteins. In order to test this hypothe-
sis, LTRG4-forming sequences were incubatedwith nuclear
protein extracts. LTR sequences of different lengths were
employed to check whether individual G4 structures identi-
fied in the LTR promoter displayed different protein bind-
ing capabilities. In particular, we assayed sequences that
possessed the minimal requirements to fold into an indi-
vidual G-quadruplex (i.e. only 4 G-tracts: LTR-II, LTR-
III and LTR-IV) and sequences capable of providing mul-
tiple G4s (i.e. more than 4 G-tracts: LTR-II+III+IV and
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Figure 1. EMSA analysis of cellular and viral proteins binding to the G4
LTR sequences. (A) Sequence of theG-richLTR region spanning−92/−48
nts. G bases in G-tracts or involved in G-quadruplexes are shown in bold.
G-tracts are numbered. Brackets indicate sequences used in this study that
form G-quadruplexes with three stacked tetrads. (B) Analysis of cellular
proteins that bind to the LTR sequences. Protein nuclear extracts (NE) of
293T and Jurkat cells were incubated with the different length G4 LTR
sequences. Binding was analysed by native polyacrylamide gel. Lane num-
bers correspond to the different LTR sequences, as shown in the legend
at the right bottom of the gel image. Length of the LTR oligonucleotides
is shown in brackets (see also Supplementary Table S1 for reference). The
relevant protein/DNA complex band present in all G4 LTR sequences is
indicated by the arrow. (C) Analysis of viral proteins that bind to the LTR-
II+III+IV sequence. Cell extracts (CE) of 293T cells either non-producing
or producing HIV-1 were incubated with the LTR-II+III+IVG4 and anal-
ysed by native polyacrylamide gel. The relevant protein/DNA complex
band present in all G4 LTR sequences is indicated by the arrow. D) West-
ern blot analysis of cell extracts (CE) of 293T cells either non-producing
or producing HIV-1. The effective presence of the virus in transfected cells
was evaluated with a HIV-1 p24 antibody.
LTR-III+IV) (Figure 1A). The corresponding 32P-labeled
oligonucleotides were incubated with nuclear extracts de-
rived from two cell lines: Jurkat T-lymphocytes that are a
model for the natural HIV-1 targets in vivo; human em-
bryonic kidney 293T cells that lack HIV-1 cell receptors
and sustain all viral steps with the exception of virion at-
tachment and entry. The latter can however be transfected
with the HIV-1 proviral genome to produce fully compe-
tent and infectious viral particles, which indicates that their
cytoplasmic/nuclear protein makeup is competent to sus-
tain viral replication. Samples were analysed onto native
polyacrylamide gels tomonitor the formation of slower run-
ning bands corresponding to oligonucleotide-protein com-
plexes. As shown in Figure 1B, all G4 LTR oligonucleotides
formed slower running bands. The fact that the patterns ob-
tained from the two nuclear extracts were essentially identi-
cal indicated that the selected cell lines contained very sim-
ilar sets of G4-binding proteins. In particular, a very spe-
cific band migrated with the same rate in all G4 oligonu-
cleotide samples (arrow in Figure 1B), thus suggesting that
the same protein was able to bind all LTR G4 sequences
considered. The intensity of the observed bands indicated
that the longer sequence (i.e. LTR-II+III+IV) was bound
most efficiently, whereas the shorter sequence (i.e. LTR-IV)
supported only very modest complex formation. The LTR-
II+III+IV oligonucleotide was incubated with extracts of
HIV-1 producing and non-producing 293T cells to test
whether the presence of viral proteins affected in any de-
tectable way the observed EMSA profiles (Figure 1C). The
actual presence of viral proteins in the transfected cells was
assessed by western blot analysis (Figure 1D). While viral
proteins were well represented in the transfected extract,
the EMSAdeterminations revealed nomajor difference and
confirmed that cellular proteins must constitute the major
players in LTR G4 binding (Figure 1C).
In previous work, we demonstrated that one- or two-
nucleotide point mutations in the G-tracts involved in G4
pairing were able to partially or totally disrupt, respectively,
G4 folding in the LTR sequence (LTR-M4, LTR-M5, LTR-
M4+5), whereas a mutation in the loop was not (LTR-M3”,
Figure 2A) (30). Based on these observations, we used mu-
tant LTR-II+III+IV oligonucleotides to assess the speci-
ficity of the observed protein for the G4 structure (Fig-
ure 2B). When incubated with the nuclear extracts, only the
sequences that retained G4-folding capabilities (i.e. wt and
M3”) were able to form bands corresponding to the desired
complexes (arrow in Figure 2B), whereas the mutants that
partially fold or cannot form stable G4s were much less effi-
ciently bound. A scrambled sequence matching the wt base
composition did not bind at all (Figure 2B and C). It should
be noted that both a slower and a faster running bands were
present in all samples (see asterisk in Figure 2B), indica-
tive of nucleic acid binding proteins that may not be se-
lective for G4. A competition experiment was performed
to confirm the binding specificity of the selected protein,
which involvedmixing the labeled wt sequence with increas-
ing amounts of unlabeled wt, mutant LTRs or scrambled se-
quence. As shown in Figure 2D and E, only the wt andM3”
sequences were able to effectively compete for protein bind-
ing, whereas the other oligonucleotides did not decrease the
amount of protein bound to wt. Interestingly, however, 10-
fold addition of M4, M5 and M4+5 oligonucleotides in-
creased the amount of protein bound to the wt sequence.
In this case, the mutant sequences may compete for bind-
ing to proteins that are sequence- but not structure-specific,
thus leaving more G4-specific protein available to bind to
the G4-folded wt sequence. Furthermore, the fact that wt
sequences folding G4 or ds structures bound different pro-
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Figure 2. Binding of nuclear extract proteins to the wild-type (wt) and mutant LTR-II+III+IV sequences. (A) Sequences of the wt and mutant LTRs.
G-tracts are shown in bold and are numbered (2–6’) above the sequence. In the mutant sequences, the mutated bases are shown in red. The names of the
mutant sequences correspond to the G-tracts where G bases have been mutated. Scra stands for a sequence where Gs have been scrambled to such an
extent that no G4 can form. The ability of the mutant sequences to fold into G4 is reported on the right: y = folding, y/n = partial folding, n = no folding
(measured as reported in (30)). (B) Binding of nuclear extract proteins to the wt and mutant labeled G4 LTR sequences. The G4-specific protein/DNA
complex is indicated by the arrow, while the asterisks indicate non-specific protein/DNA complexes. (C) Quantification of G4-specific protein/DNA
complex reported in (B). (D) Competition of the G4-specific protein/DNA complex with unlabelled wt and mutant LTR sequences. The molar excess of
the competitor sequences is shown above each lane. (E) Quantification of G4-specific protein/DNA complex reported in (D). The arrows indicate the only
two unlabeled sequences able to compete the wt LTR/protein complex. (F) Binding of different amounts of nuclear extract proteins to the wt G4 folded
and ds LTR-II+III-IV sequences.
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teins confirmed that the observed protein was specific for
the G4 conformation (Figure 2F).
Nucleolin specifically recognizes and stabilizes the LTR G-
quadruplexes
With the goal of identifying the protein of interest, the rel-
evant EMSA band was excised from the gel and submit-
ted directly to trypsin digestion (see Materials and Meth-
ods). Alternatively, the material extracted from the EMSA
band, which could possibly include multiple co-migrating
species, was further purified on a SDS gel before trypsin di-
gestion. In either case, the digestion products were subjected
to MS/MS analysis and database searching (Figure 3A)
(40,41), which provided an excellent match with human nu-
cleolin (NCL) (Table 1). The experiment was separately re-
peated three times to corroborate the results. Positive iden-
tification was also confirmed by performing EMSA anal-
ysis of samples that included the G4-folded wt and mu-
tant LTR-II+III+IV sequences with either nuclear extracts
or purified human NCL. NCL displayed the same binding
activity towards the wt and mutant LTR sequences mani-
fested by the unknown protein (Figure 3B). NCL binding
to the wt LTR-II+III+IV G4 was concentration dependent
(Figure 3C and D). Surprisingly, however, two NCL/LTR
complex bands were identified (Figure 3B and C). It has
been reported that both native and purified NCL display
self-cleaving activity and indeed preparations of NCL usu-
ally exhibit multiple bands (42). Our purified NCL also
showed multiple bands on SDS gel, as detected by both
Coomassie staining and western blot analysis (Supplemen-
tary Figure S1A). MS analysis of the four bands detected
by Coomassie staining showed full-length peptide coverage
only for the upper major band, whereas coverage of the
N-terminal portion was missing in the lower three bands
(Supplementary Figure S1B). We therefore ascribed the up-
per and lower bands to the full-length and cleaved forms
of NCL, respectively. Interestingly, the band obtained from
nuclear extracts migrated the fastest and, indeed, the N-
terminal portion was not observed by MS peptide analy-
sis (Table 1 and Supplementary Figure S1B). In addition,
when the protein bound to LTR G4 in the EMSA gel was
extracted and analyzed separately on SDS gel, it migrated
at around 75 kDa, corresponding to one of the cleaved
forms of NCL (data not shown). Therefore, we conclude
that the NCL form present in the nuclear extracts corre-
sponds to its cleaved portion lacking the N-terminus. In ad-
dition, NCL formed a complex with a scrambled sequence,
which displayed a slightly slower migration rate compared
to the G4-bound NCL (Figure 3B). The amount of com-
plex was similar to that afforded by M4 and M5 LTR se-
quences. Binding of NCL to G-rich oligonucleotides has
been previously reported (43) and provides an excellent in-
dication that the RNA binding domains (RBD) of the puri-
fied NCL are indeed active. In analogous fashion, biotiny-
lated wt, M4+5 LTR-II+III+IV, and scrambled-sequence
oligonucleotides were incubated with nuclear extracts and
then added to streptavidin-functionalized agarose beads to
facilitate removal of unbound proteins. Immobilized pro-
teins were eluted with buffers of increasing ionic strength
and identified by western blot analysis (Figure 3E). NCL
was released from the wt sequence when treated with in-
creasing concentrations of NaCl or heated to 95◦C in de-
naturing buffer, whereas it was released from theM4+5 and
scrambled sequences at the lowestNaCl concentration, con-
sistent with a lower affinity for these non-G4-forming se-
quences. These data confirm thatNCL specifically binds the
G4 folded conformation of the LTR-II+III+IV sequence.
Taq polymerase stop assays were performed to assess
the stabilization imparted by NCL to the various LTR G4
structures. The wt LTR-II+III+IV and M4+5 mutant se-
quences were extended to include a primer-annealing re-
gion and used as templates for a single-cycle Taq reaction
(Supplementary Table S1). Elongation of the wt template
was performed at 37◦C or 47◦C in the presence/absence of
NCL. In samples containing 100 mM KCl and no NCL, a
pausing site corresponding to the most 3′-end G-tract was
observed only in the reaction elongated at 37◦C. The pause
was not observed at 47◦C, consistent with possible desta-
bilizing effects of temperature on the G4 structure (com-
pare lanes 2 and 5 of Figure 4A). Addition of NCL induced
more evident pauses at both elongation temperatures (Fig-
ure 4A, lanes 3 and 6), which clearly highlighted the stabi-
lizing properties of NCL on G4 conformation. As expected
from the inability of the M4+5 mutant to fold G4 struc-
tures, no pausing sites were observed regardless the pres-
ence of protein (Figure 4A, lanes 7–9), thus confirming the
specificity of NCL binding for full-fledgedG4s. At the same
time, FRET melting assays were also carried out to study
the stabilizing effects of NCL on the G4 structures. The as-
says involved the synthesis of constructs that combined se-
lected G4-forming sequences, such as LTR-II+III+IV and
the shorter LTR-II, LTR-III, LTR-IV, and LTR-III+IV
(Figure 2A), with FAM and TAMRA moieties placed at
their 5′- and 3′-ends, respectively. The results showed that
NCL conferred the highest stabilization in the series to the
LTR-II+III+IV construct, followed by LTR-III+IV. Pro-
gressively lower stabilization was observed for LTR-III and
LTR-II, whereas LTR-IV was the least affected in the se-
ries (Table 2). The negative control bovine serum albumin
(BSA) did not afford any detectable stabilization to the se-
lected sequences.
To identify the position of putative NCL binding sites
onto the DNA G4 structures, we performed dimethylsul-
fate (DMS) footprinting. When a complex of NCL with the
LTR-II+III+IV DNAwas assessed (Figure 4B), the methy-
lation pattern revealed that the 3′ region of the LTR se-
quence was protected by protein binding with unique speci-
ficity for two G bases in G-tract 4, as highlighted in Fig-
ure 4C.
Based on the facts that NCL has been described as a
RNA-binding protein (44) and that the LTR sequence is
present in the U3 region of the HIV-1 genome during the
initial infection steps, we tested whether NCL could also
bind the RNA version of the LTR G4. In this case, NCL
was incubated with labeled RNA or DNA oligonucleotides
capable of folding LTR G4s. Increasing concentrations of
unlabelled RNA and DNA counterparts were employed to
compete for NCL binding. The results clearly showed that
the protein was able to bind both types of G4 oligonu-
cleotides (lanes 1 and 6, Figure 5A). However, the DNA
G4 was consistently able to outcompete the RNA version
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Figure 3. Identification of the G4-specific LTR binding protein. (A) MS/MS spectrum of the precursor ion observed atm/z 1251.14 in the sample mixture
from native gel 1 (see Table 1). Only characteristic b and y ions are indicated (40,41). The data matched the sequence of peptide T487-K508 of NCL, which
is reported on top with the observed fragments. (B) EMSA analysis of the binding of nuclear extract (NE) proteins and purified NCL to the wt and mutant
LTR sequences. Arrows indicate relevant protein/LTRG4 complex bands. (C) EMSA analysis of the binding of increasing amounts of purified NCL to the
wt LTR-II+III+IV G4. The vertical bar highlights the portion of the gel where the two NCL/LTR G4 complex bands are observed. (D) Quantification of
the upper and lower NCL/LTRG4 complex bands obtained in the EMSA in panel (C). (E) Pull-down assay of nuclear extract proteins with wt, mutant G4
LTR-II+III+IV and random (rnd) sequences, immobilized on agarose beads. Shown is the western blot analysis with anNCL antibody. Proteins complexed
to the beads-bound LTRs were washed with augmented stringency by increasing the ionic strength of the wash buffer (0.2 and 1 M). The final elution was
obtained in denaturing buffer at 95◦C.
Table 1. MS analysis of protein content of three gel bands collected from one SDS gel and two native gels
Sample
Experimental
monoisotopic mass
Expected
monoisotopic mass Protein match Peptide match Score
SDS gel 2199.02 2199.02 Nucleolin (G578-R597) 22
1647.73 1647.73 Nucleolin (F349-K362) 63
1560.67 1560.67 Nucleolin (G611-K624) 68
Native gel 1 4856.25 4856.26 Translationally-
controlled tumor
protein
(T39-K85) 22
2500.26 2500.26 Nucleolin (T487-K508) 102
2311.14 2311.15 Nucleolin (V298-K318) 84
1647.73 1647.73 Nucleolin (F349-K362) 71
Native gel 2 2500.26 2500.26 Nucleolin (T487-K508) 93
2311.14 2311.15 Nucleolin (V298-K318) 62
2199.02 2199.02 Nucleolin (G578-R597) 30
1560.67 1560.67 Nucleolin (G611-K624) 60
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Table 2. FRET analysis of the stabilization of NCL on the different length G4 LTR sequences
LTR sequence Tm LTR (◦C) Tm LTR + NCL (◦C) Tm (◦C)
LTR-II 58.1 ± 0.2 76.2 ± 1.4 18.1
LTR-III 63.1 ± 0.1 75.1 ± 0.7 12.0
LTR-IV 62.1 ± 0.6 69.0 ± 1.4 6.9
LTR-III+IV 54.0 ± 0.6 78.5 ± 2.5 24.5
LTR-II+III+IV 48.0 ± 0.6 86.9 ± 1.4 38.9
Figure 4. Characterization of NCL binding to the G4 LTR-II+III+IV.
(A) Taq polymerase stop assay. Taq polymerization was performed in the
presence/absence ofK+ andNCL, as indicated, on the wt andM4+5LTR-
II+III+IV sequences. Amplification of the wt template was performed at
37◦C and 47◦C; on the mutant template elongation was obtained at 37◦C.
Stop regions are highlighted by the * symbol. (B) DMS protection analy-
sis of the NCL/LTR complex and the G4 LTR-II+III+IV oligonucleotide.
Band cleavage intensity is quantified by a densitogram shown on the right:
red and blue lines correspond to the LTR andNCL/LTR complex, respec-
tively. G-tracts and their numbering are indicated on the left. The two gel
portions derive from a single gel run. (C) The LTR-II+III+IV sequence:
bases protected by theDMS alkylation/cleavage are shown in red. The font
of the red letters is proportional to the protection. G-tracts are numbered.
for protein binding (lanes 7–10, Figure 5A and B), whereas
the RNA was incapable of outcompeting the DNA (lanes
2–5, Figure 5A and B). We had previously shown that the
LTR RNA G4s fold into parallel structures (33), whereas
the DNA counterparts display rather hybrid-like confor-
mations (30); therefore, the preferential binding toward the
DNAG4 is likely caused by these substantial structural dif-
ferences between the DNA and RNA G4 conformations.
Surface plasmon resonance (SPR) analysis was next used
to assess the affinity of the purified NCL for the wt LTR-
II+III+IV G4: a KD of 2.5 ± 0.1 nM was obtained, which
indicates an extremely high affinity of the protein for this
LTR G4 (Figure 5C). In contrast, the scrambled oligonu-
cleotide showed no affinity forNCL (Supplementary Figure
S1).
Binding of nucleolin to the LTRG-quadruplexes increases re-
pression of viral transcription
A luciferase reporter assay was established to explore the
downstream biological effects of NCL binding to the LTR
promoter. Two epithelial breast cell lines were selected for
the assay:MCF-7 breast cancer cells andMCF-10A normal
breast epithelial cells. The latter inherently express lower
amounts of NCL compared to tumor cells (45,46). For this
reason, the MCF-10A cells were transfected with wt or
M4+5 LTR luciferase reporter plasmids, either alone or in
the presence of increasing amounts of NCL expression vec-
tor. The luciferase signal was measured to determine the
level of activation of the LTR promoter. The results showed
that the activity of wt LTR decreased to 65% of the con-
trol, while that of the M4+5 promoter remained unvaried
(Figure 6A). The MCF7 cell line that overexpresses NCL
was employed to perform additional activity assays. In this
case, cells were treated with increasing amounts of siRNAs
designed to target NCL mRNA (47), and then transfected
with wt or mutant M4+5 LTR luciferase reporter plasmids.
Analysis of NCL content showed that the protein was effec-
tively depleted at 1–4 nM siRNA, reaching 8% of the initial
amount at 4 nM (Figure 6B). Measured by luciferase activ-
ity, the effect of NCL depletion on LTR promoter activity
was quite astonishing: at 4 nM of siRNA, the promoter ac-
tivity of the wt sequence was 37 folds that of the control
while the mutant M4+5 sequence was only 1.5 folds (Fig-
ure 6C). As a complementary approach, we tested the ef-
fect of the NCL-targeted DNA aptamer AS1411, which has
been reported to bind with high affinity NCL in cells (48).
At 1 M of AS1411, we again observed a significant incre-
ment of the wt LTR promoter activity to reach 11 times that
of the non-treated control while the mutantM4+5 sequence
increased of only 2.5 times (Figure 6D). In contrast, the
control sequence CRO26 that is complementary to AS1411
did not modify LTR promoter activity. These data indicate
that the specific binding ofNCL toG4 structures in theLTR
promoter exerts significant repressive effects on HIV-1 pro-
moter activity.
DISCUSSION
We have identified NCL as a prominent host factor capable
of binding with high affinity to the G4 structures present
in the LTR promoter of HIV-1. We observed that the spe-
cific interaction leads to G4 stabilization and contributes
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Figure 5. Properties of NCL binding to the G4 LTR-II+III+IV sequence.
(A) EMSA competition analysis of NCL binding towards the G4 LTR-
II+III+IV DNA and RNA sequences. On the left: the labeled G4 LTR
DNA* was bound to NCL and competed with increasing folds of unla-
belled G4 LTRRNA (1–50 folds); on the right, the labeled G4 LTRRNA*
was bound to NCL and competed with increasing folds of unlabelled G4
LTR DNA (1–50 folds). C is a control lane for the oligonucleotides before
binding. (B) NCL/LTR complex band quantification of the experiment
presented in (A). (C) SPR binding analysis of wt LTR-II+III+IV to im-
mobilized NCL. Oligonucleotide concentration range was 31.25 nM-2000
nM. Sensograms are shown as gray lines and their respective fits as black
lines.
Figure 6. Activity of NCL on the HIV-1 LTR promoter in cells. (A) Analy-
sis of the luciferase activity of the wt and M4+5 LTR promoters in MCF-
10A cells transiently transfected with the LTR luciferase plasmids and a
NCL expression plasmid. (B) NCL depletion in MCF7 cells by NCL siR-
NAs analysed by western blot with NCL antibody. Scra indicates scram-
bled siRNAs. Detection of -actin was used as control. The % of NCL
expression in each sample is given below the gel. (C) Analysis of the lu-
ciferase activity of the wt andM4+5 LTR promoters inMCF7 cells treated
with NCL siRNAs. (D) Analysis of the luciferase activity of the wt and
M4+5 LTR promoters in MCF7 cells treated with the NCL-binding ap-
tamer AS1411 and the negative control CRO26.
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to silence viral transcription. Conversely, we also demon-
strated thatNCLdepletion produces extraordinary enhanc-
ing effects on LTR promoter activity. These observations
are consistent with the multifaceted nucleic acid binding
and chaperoning activities attributed to this protein. In-
deed, NCL is most abundant in the nucleolus, but can be
found also in cell membranes and, upon stress stimuli, in the
nucleoplasm and cytoplasm, to some extent (49,50). Among
other functions, it is involved in transcription (50) by spe-
cific interactions with sequences that can adopt complex
secondary structures (44,51–52). It is widely believed that
NCL plays a chaperone role by helping the correct fold-
ing of complex nucleic acids structures. Indeed, NCL has
been shown to display a marked preference for both en-
dogenous and exogenous G-rich sequences that can fold
into G4 (53). It has been recently reported that binding of
NCL to the endogenous (GGGGCC)n hexanucleotide re-
peat expansion (HRE) in C9orf72 is responsible for the ini-
tiation of molecular cascades that lead to neurodegenera-
tive diseases (19). At the promoter level, binding of NCL to
G4 structures augments the basal effect of the folded con-
formation (45,54–56). One of the best documented exam-
ple of G4-mediated regulation among G4 promoters (57) is
that of c-myc, which shows striking similarities with theG4-
mediated regulation of the HIV-1 LTR promoter reported
here and previously by us (30). Both cases involve multiple
G-tracts that enable folding into alternative G4 conforma-
tions; G4 parallel-like topology (58); at least one G3N1G3
motif; binding sites for SP1; silencing effect on promoter ac-
tivity (59);NCL-binding activity and higher affinity ofNCL
towards the DNA G4 compared to the RNA G4 counter-
part (45). In the case of c-myc, it has been shown that the
N-terminal ofNCL is dispensable for itsG4 binding activity
(56). Here, we show thatNCL can naturally produce cleaved
forms that lack the N-terminal but retain full binding ca-
pabilities. These observations demonstrate that cells allow
the formation of NCL cleaved species that maintain their
G4/nucleic acid binding activity. On the other, they sug-
gest that the HIV-1 virus and human host cells have likely
evolved identical mechanisms to control transcription at the
DNA promoter level.
The results of our experiments provided valuable insights
into the determinants of NCL binding to the various LTR
G4-forming structures. The lower binding of NCL to LTR-
IV compared to the otherG4 structures suggests that the in-
teraction has both conformation- and sequence-dependent
characteristics, which in turn implies the fascinating possi-
bility that different G4s in the HIV-1 LTR promoter may
exert different functions based on their binding partners.
Moreover, the greater affinity demonstrated for DNA than
RNA constructs indicates that the interaction is deeply in-
fluenced by conformational differences between G4 struc-
tures folded by the different types of biopolymers. The facts
that the HIV-1 genome consists of RNA, that this G4-
forming sequence is also present in the U3 region of the
genome (33), and that viral RNA during the first steps of
infection is still present in the cell cytoplasm where NCL
levels are low, suggest that the specific binding of NCL
to the DNA version may represent an essential mecha-
nism for regulating viral transcription. In this direction, it
has been shown that NCL is involved in different steps of
the HIV-1 life cycle. Inhibition of surface NCL by differ-
ent cellular and synthetic compounds (60–62) affects cell
attachment/entry by the virus (63). In addition, NCL can
bindHIV-1Gag protein to promote viral budding (64), or to
enhance Gag release (65). Further, NCL involvement in the
viral life cycle has been corroborated also by evidence that
HIV infection modifies the protein’s cellular distribution
(66,67). The activities performed by NCL in other viruses
have also been described in a number of recent papers (68–
72). For example, binding of NCL to Epstein–Barr virus
(EBV) nuclear antigen 1 (EBNA1) modulates viral repli-
cation and transcription (73), and virus-induced relocaliza-
tion ofNCLhas been observed in some instances (74,75). In
this broader context, these reports support our new findings
that point toward a significant role played by this protein in
HIV-1 replication.
The observation that NCL interaction with LTR G4 si-
lences viral transcription is in apparent contrast with the
well-known ability of NCL to interact with histone H1,
which induces chromatin decondensation (76) that in turn
facilitates the passage of the DNA polymerases (77). How-
ever, the opposite effect consisting ofNCL-mediated repres-
sion of DNA replication has been also reported (49,78–80),
and has been attributed to the interaction of NCL with the
DNA processing enzyme Replication Protein A (RPA). In
addition, NCL has been reported to recruit a DNA heli-
case that unwinds G4 structures (81). In both cases, NCL
binding to cellular proteins is a transient response to stress
stimuli. These observations prompt the intriguing possibil-
ity that when NCL is redistributed by the cellular stress im-
posed by HIV infection (66,67), it may be then recruited
by the G4 structure of viral promoter to transiently down-
regulate HIV transcription and enable the virus to prepare
for subsequent efficient transcription, when viral proteins,
such as Tat, take over. Alternatively, this interaction may
be required as a first switch to viral latency and to recruit
proteins that further consolidate latency. The signals that
trigger latency are not known at this point and are thus the
object of intense studies. However, factors that repress viral
transcription at the LTR promoter have been proposed to
play a determinant role in latency mechanisms (82,83). Fi-
nally, the very specific nature of nucleolin binding indicates
that its viral target must be less prone tomutations. This ob-
servation makes the viral G4/nucleolin complex into a very
appealing target for the development of antiviral strategies
that may afford a different mechanism of action, the possi-
bility of targeting viral latency, and a lower probability of in-
curring into drug resistance. In conclusion, we have shown
that the specific binding of the cellular protein NCL to
the LTR promoter regulates viral transcription. This result
alone paves the way for the investigation of different reg-
ulation mechanisms of HIV-1 transcription/latency, which
may lead to new possible targets for the design of specific
inhibitors.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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